image description

Tag: LRA

Investigational CAR T Cell Gets Fast Tracked by U.S. FDA

May 1, 2023 The LRA and our clinical arm Lupus Therapeutics are pleased to share good news from Cabaletta Bio, Inc. that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CABA-201, a CAR T cell investigational therapy in development to treat systemic lupus erythematosus and lupus nephritis – a common […] Read More

New COVID-19 Vaccine Clinical Guidance and Planned Research

Important news for people with lupus as COVID-19 vaccines are on everyone’s minds.  The foremost authority in rheumatologic diseases, the American College of Rheumatology (ACR) recently issued the COVID-19 Vaccine Clinical Guidance. Developed by a panel of rheumatologists, specialists in infectious disease and public health experts, the Guidance aims to help healthcare providers make decisions with their […] Read More

2019 Lupus Insight Prize Awarded to Ignacio Sanz, MD

Thinking outside the box” is jargon that often rings hollow—but not so when it’s used to describe the ideas generated by Ignacio Sanz, MD, world-renowned expert on autoimmunity. Dr. Sanz recently discovered that certain little-understood immune system cells are a major source of the harmful proteins that promote lupus symptoms. This breakthrough has the potential […] Read More

Leading with Extraordinary Clarity and Grace

Leading with Extraordinary Clarity and Grace The LRA is enormously grateful to Mary K. (Peggy) Crow, MD for her more than 10 years of devoted service and leadership as the organization’s Co-Chair of our Scientific Advisory Board. Dr. Crow’s tenure concludes on December 31st. “It’s well known that Dr. Crow has brought vision … leadership […] Read More

Lupus News Corner

BIG … BOLD … IDEAS ARE TRANSFORMING LUPUS RESEARCH—thanks to people like you! Thanks to our remarkable supporters, the Lupus Research Alliance awarded nearly $7.5 million through the following grant mechanisms in 2019: 2019 Novel Research Grants ($1,798,602) Carla Cuda, PhD The Role of Microglial Subsets in Driving Neuropsychiatric Symptoms of SLE Northwestern University – Chicago […] Read More

LRA-Funded Discovery May Benefit Alzheimer’s Disease

August 1, 2019 A new study by LRA Distinguished Innovator Award recipient Dr. Douglas Green of St. Jude Children’s Research Hospital in Memphis, TN, and colleagues may have uncovered a new way to treat Alzheimer’s disease. The research, highlighted recently in Forbes magazine and published in the journal Cell, identified one of the brain’s mechanisms […] Read More

Illuminating the Microbiome’s Role in Lupus

May 15, 2019 One of the biggest questions in lupus is why the immune system tries to destroy patients’ own tissues. But in the last few years, researchers have learned that certain microbes living inside our bodies may trigger these attacks. Scientists supported by the Lupus Research Alliance (LRA) have made many of the key […] Read More

Seeing Our Research Through a Fresh Lens With Dr. Gary Koretzky

April, 2019 The Lupus Research Alliance is proud to welcome renowned expert in rheumatology and immunology, Gary Koretzky, MD, PhD, as co-chair of our Scientific Advisory Board (SAB). He will co-chair the SAB with the distinguished Dr. Mary “Peggy” Crow. Dr. Crow is Physician-in-Chief and Chair of the Department of Medicine at Hospital for Special […] Read More

Lupus Research Alliance and National Minority Quality Forum Release Recommendations to Advance New Lupus Treatments by Increasing Diversity in Clinical Trial Participation

NEW YORK, NY. March 14, 2019.  The Lupus Research Alliance (LRA) and the National Minority Quality Forum (NMQF) today released the insightful report, Addressing the Challenges of Clinical Research Participation Among Populations Disproportionately Impacted by Lupus. The report presents findings and actionable recommendations ranging in scope that can be implemented by any individual or group seeking […] Read More

LRA-funded Research Backs New Lupus Nephritis Clinical Trial

February 28, 2019 The biotechnology company Equillium Inc. just announced plans for a Phase 1 study to test the investigational monoclonal antibody EQ001 as a potential treatment for lupus nephritis (LN) that has not responded to existing treatment. The basis for this study is in part due to work conducted by Dr. Chandra Mohan that […] Read More